In this setting, the secretion of cyto/chemokines, along with T cell activation levels measured in a PDE model of patient-derived tumor fragments (PDTF) from different tumor types embedded into an artificial extracellular matrix, could predict clinical response to PD-1 blockade (22). Here, PDCD1 is linked to neoplasm.